Download Mount Sinai Services Inc. Announces Partnership with Personalis to

Mount Sinai Services Inc. Announces Partnership with Personalis to
Offer its ACE Platform for Next Generation Sequencing and
Interpretation to Support Tumor Molecular Profiling and ImmunoOncology Clinical Trials in Canada
Toronto, Ontario – June 07, 2016 – Mount Sinai Services, Inc. of Toronto, Ontario, Canada, a global
provider of customized clinical laboratory and research services announced today that the company has
entered into a letter of intent (LOI) with Personalis, Inc., a leading precision medicine company focused
on advanced NGS-based clinical diagnostic and research services. The LOI contains broad terms for the
development of a partnership framework for Personalis and Mount Sinai Services to offer the Personalis
patented, and CLIA validated ACE (Accuracy and Content Enhanced) sequencing and analysis technology
for clinical diagnostic and research tumor molecular profile sequencing and analysis and immunooncology sequencing clinical trials for customers throughout Canada. The ACE Platform® incorporates
proprietary sample prep and sequencing processes which produce the highest levels of gene finishing
and coverage of difficult-to-sequence regions.
Personalis currently provides comprehensive genomic testing for tumor-profiling through its ACE
CancerPlus™ test for solid tumors. As the largest and most comprehensive cancer panel available today,
the ACE CancerPlus test combines both DNA and RNA sequencing of over 1,400 genes, using the
Personalis proprietary ACE technology. The ACE CancerPlus Test result reports out on 181 genes of
clinical relevance, producing comprehensive tumor genomic profile data to guide therapy and ongoing
research.
The ACE ImmunoID™ service offers multiple solutions for the comprehensive analysis of tumor mutation
burden and neoantigen identification including the leading ACE Cancer Exome and Transcriptome
covering over 20,000 genes and the ACE Cancer DNA/RNA Panel available with over 1,400 genes. The
Personalis ACE assays and informatics platform achieves industry leading coverage and sensitivity
enabling variants to be identified more accurately and reliably in regions that may be completely missed
by typical exomes, transcriptomes, and panels. The ACE assays together with advanced informatics are
CLIA validated to enable clinical diagnostic and clinical trials use.
“As a leading, independent clinical diagnostic and research laboratory with a strong focus on precision
medicine and diagnostics, Mount Sinai Services is delighted to work with Personalis to develop this
strategic partnership to advance cancer therapeutic development and clinical care,” said Dr. Azar Azad,
Managing Director of Mount Sinai Services. “We are confident that our expertise in providing
customized laboratory services, combined with the capabilities of the Personalis ACE Platform will
contribute to advancing translational medicine by providing a comprehensive solution for pharma
discovery and development of cancer therapies, and personalized clinical diagnostic cancer care.”
700 University Ave. Toronto Ontario M5G 1Z5 Tel: 416-586-4800 ext. 7266 Fax: 416-586-8589 email: [email protected]
http://www.mountsinaiservices.com/
“We are pleased to work with Mount Sinai Services to offer the Personalis ACE technology to support
immuno-oncology clinical trials and clinical laboratory and research tumor profiling in Canada,” said
John West, CEO of Personalis. “Mount Sinai Services has been a leader in advancing personalized
medicine in Canada and understands the complexities and value of comprehensive and accurate analysis
and interpretation in cancer research and clinical care. Their longstanding reputation for innovation and
high quality customer service provides Personalis with a technically robust partner in Canada.”
About Mount Sinai Services, Inc.
Mount Sinai Services is a CAP/CLIA and ISO 15189 certified global provider of customized clinical
diagnostic laboratory and research services. Mount Sinai Services works closely with world-renowned
clinicians and researchers at Sinai Health System, Lunenfeld-Tanenbaum Research Institute, University
of Toronto and other Canadian academic and healthcare providers to offer comprehensive services
supporting discovery and innovation in the life sciences, including medical device and diagnostic assay
development and validation, clinical trial management and providing customized services to biotech and
pharma industry. Mount Sinai Services provides specialized clinical laboratory testing throughout
Canada and supports processes to achieve new assay reimbursements.
Mount Sinai Services is committed to providing its clients with superior customer service and highquality results based on a truly collaborative approach. For information, visit
www.mountsinaiservices.com.
About Personalis, Inc.
Personalis, Inc. (www.personalis.com) a leading precision medicine company focused on advanced NGSbased clinical diagnostic and research services for cancer and inherited genetic disease. The company’s
ACE Exome technology is designed to obtain the most comprehensive and accurate genomic data tumor
burden for tumor molecular profile and immuno-oncology applications. The company’s clinical
laboratory is GCP compliant, CLIA licensed and CAP accredited.
For more information please visit www.personalis.com.
Mount Sinai Services Contact:
Azar Azad Ph.D.
Managing Director
(416) 586-4800 ext. 7266
[email protected]
Personalis Media Contact:
Jennifer Havlek
650-752-1300
[email protected]
www.personalis.com
700 University Ave. Toronto Ontario M5G 1Z5 Tel: 416-586-4800 ext. 7266 Fax: 416-586-8589 email: [email protected]
http://www.mountsinaiservices.com/